<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588132</url>
  </required_header>
  <id_info>
    <org_study_id>LeesPharm_Anfibatide_Phase1</org_study_id>
    <nct_id>NCT01588132</nct_id>
  </id_info>
  <brief_title>Anfibatide Phase 1 Clinical Trial in Healthy Volunteers</brief_title>
  <official_title>First Assessment of the Glycoprotein Ib-IV-V Complex Antagonist Anfibatide in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this 94 healthy subjects Phase I clinical trial, we assess the clinical profile of
      Anfibatide, a specific glycoprotein Ib antagonist. This study represents the first clinical
      evidence that Anfibatide exhibits strong anti-platelet effects, excellent reversibility, and
      low bleeding potential in healthy human subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoints</measure>
    <time_frame>24 Hours</time_frame>
    <description>To investigate the number of adverse events in patients with single or multiple intravenous injection/infusion of Antiplatelet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>Predose, 0,1,2,3,4,6,8,12,24,48,72,96 Hours</time_frame>
    <description>To observe area under curve characteristics of Anfibatide in single or multiple dose groups</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Coagulation Disorder</condition>
  <arm_group>
    <arm_group_label>Single dose gourp 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose groups 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide</intervention_name>
    <description>To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.
To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.</description>
    <arm_group_label>Single dose gourp 1</arm_group_label>
    <arm_group_label>Single dose group 2</arm_group_label>
    <arm_group_label>Single dose groups 3</arm_group_label>
    <arm_group_label>Single dose group 4</arm_group_label>
    <arm_group_label>Single dose group 5</arm_group_label>
    <arm_group_label>Single dose group 6</arm_group_label>
    <arm_group_label>Single dose group 7</arm_group_label>
    <arm_group_label>Single dose group 8</arm_group_label>
    <arm_group_label>Multiple dose group 9</arm_group_label>
    <arm_group_label>Multiple dose group 10</arm_group_label>
    <arm_group_label>Multiple dose group 11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Healthy volunteers, aged 18-28 years, male and female were included, age difference
             less than 10 years;

          -  2) Body weight: with body mass index (BMI) between 19-24, difference less than 10kg in
             the same group, BMI=body weight(kg)/height2;

          -  3) Past medical history: no history of heart, liver, kidney, digestive tract, nervous
             system and metabolic disorder, or ulcer, significant hemorrhage, without the history
             of drug allergy and postural hypotension;

          -  4) Medical examinations: with normal results in overall examinations (including heart
             rate, blood pressure, auscultation of heart and lung, palpation of liver and spleen,
             hepatic and renal function, hematology, coagulation function, urine analysis, stool
             analysis and occult blood test, electrocardiogram);

          -  5) Have not received any medications within 2 weeks before the study;

          -  6) Willing to participate in the study and give a signed informed consent form after
             understanding the study procedures and potential adverse reactions of the study
             product.

        Exclusion Criteria:

          -  1) History of HBV or HCV infection;

          -  2) Addicted to smoking or alcohol;

          -  3) Women during pregnancy, lactation or menstrual period;

          -  4) Past history of hemoptysis, bloody stool, bleeding spots in the skin and mucous
             membrane, or hemorrhagic tendency (find themselves prone to bleeding in gums, nose,
             skin and mucous membrane, or hemoptysis);

          -  5) History of active bleeding (such as peptic ulcer, hemorrhoids, active tuberculosis,
             subacute bacterial endocarditis, etc);

          -  6) Blood platelet count less than 150×109;

          -  7) Trauma history (e.g., craniocerebral trauma) recently;

          -  8) Past history of unexplained syncope or convulsion;

          -  9) History of organic or psychogenic disease or the disabled;

          -  10) Persons who were unlikely to participate in the study (such as the infirm) in the
             investigator's opinion;

          -  11) Have donated blood or experienced blood collection in other trials within 3
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>28 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lee's Pharmaceutical Limited</investigator_affiliation>
    <investigator_full_name>Vivian Fung</investigator_full_name>
    <investigator_title>Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

